We have recently reported that response rate, progression free survival and overall survival is significantly greater in BRAF mutant CRC patients with the BM1 transcriptional sub-type than the BM2 sub-type when treated with combined BRAF/MEK/EGFR inhibition [17]. This evidence concerns the gene BRAF and colorectal carcinoma.